159 related articles for article (PubMed ID: 22534502)
21. Treatment of benign essential blepharospasm with finasteride: a case report.
Bortolato M; Cannas A; Solla P; Puligheddu M; Muroni A; Marrosu F
Clin Neuropharmacol; 2010 Jul; 33(4):207-8. PubMed ID: 20386102
[TBL] [Abstract][Full Text] [Related]
22. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Parkinson's disease.
Boyson SJ
Neurology; 1990 Apr; 40(4):725. PubMed ID: 2320258
[No Abstract] [Full Text] [Related]
24. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
25. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
26. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Klivényi P; Vécsei L
Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774
[TBL] [Abstract][Full Text] [Related]
27. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
[TBL] [Abstract][Full Text] [Related]
28. Levodopa-associated hemifacial dystonia.
Mark MH; Sage JI
Mov Disord; 1991; 6(4):383. PubMed ID: 1758464
[No Abstract] [Full Text] [Related]
29. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
30. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Olanow CW; Alberts MJ
Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
[No Abstract] [Full Text] [Related]
31. Clinical inquiry. Which drugs work best for early Parkinson's disease?
Jain L; Benko R; Safranek S
J Fam Pract; 2012 Feb; 61(2):106-8. PubMed ID: 22312616
[TBL] [Abstract][Full Text] [Related]
32. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
34. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Greene P; Cote L; Fahn S
Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
[No Abstract] [Full Text] [Related]
35. [Drug therapy of Parkinson's disease].
Zhou XD
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
[No Abstract] [Full Text] [Related]
36. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Simonson W; Hauser RA; Schapira AH
Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
[TBL] [Abstract][Full Text] [Related]
37. Stalevo for Parkinson's disease.
Med Lett Drugs Ther; 2004 May; 46(1182):39-40. PubMed ID: 15136772
[No Abstract] [Full Text] [Related]
38. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
[TBL] [Abstract][Full Text] [Related]
39. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Wilson L; Sheehan J; Thorpe M
Ir Med J; 2013 Jan; 106(1):24-5. PubMed ID: 23472375
[TBL] [Abstract][Full Text] [Related]
40. Medical treatment of Parkinson's disease.
Ahlskog JE
Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]